Evidence map›Paper›PMID 29063312›Full record

ArticleBreast cancer research and treatment2018

Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance.

Jérôme Abadie, Frédérique Nguyen, Delphine Loussouarn, Laura Peña, Adelina Gama, Natascha Rieder, Anton Belousov, Ingrid Bemelmans, Laëtitia Jaillardon, Catherine Ibisch and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Breast cancer research and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 1 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 1 synthesis or guideline pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 4 countries.

Jérôme AbadieOniris, Nantes Atlantic College of Veterinary Medicine, Food Science and Engineering, Animal cancers, Models for Research in Comparative Oncology (AMaROC), Site de la Chantrerie, Route de Gachet, CS40706, 44307, Nantes, France. jerome.abadie@oniris-nantes.fr.ORCID 0000-0002-7750-0519
Frédérique NguyenOniris, Nantes Atlantic College of Veterinary Medicine, Food Science and Engineering, Animal cancers, Models for Research in Comparative Oncology (AMaROC), Site de la Chantrerie, Route de Gachet, CS40706, 44307, Nantes, France.
Delphine LoussouarnCRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.
Laura PeñaDepartment of Animal Medicine, Surgery and Pathology, Complutense University of Madrid, Madrid, Spain.
Adelina GamaAnimal and Veterinary Research Centre (CECAV), University of Trás-os-Montes and Alto Douro (UTAD), Vila Real, Portugal.
Natascha RiederPathology and Tissue Analytics, Pharma Research & Early Development, Roche Innovation Center Munich, Munich, Germany.
Anton BelousovPharmaceutical Sciences, Pharma Research & Early Development, Roche Innovation Center Munich, Munich, Germany.
Ingrid BemelmansCerba Vet, Wissous, France.
Laëtitia JaillardonOniris, Nantes Atlantic College of Veterinary Medicine and Food Sciences, LDHVet, Nantes, France.
Catherine IbischOniris, Nantes Atlantic College of Veterinary Medicine, Food Science and Engineering, Animal cancers, Models for Research in Comparative Oncology (AMaROC), Site de la Chantrerie, Route de Gachet, CS40706, 44307, Nantes, France.
Mario CamponeCRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.
Inserm · FRRoche Pharma AG (Germany) · DEOniris · FRUniversidad Complutense de Madrid · ESUniversity of Trás-os-Montes and Alto Douro · PT

Funding

INCa 201108INCa INCa-DHOS 2010
6 · The paper itself

Abstract

purposeRelevant animal models of human breast cancer are currently needed, especially for the aggressive triple-negative breast cancer subtype. Recent studies and our results (Part 1) indicate that spontaneous canine invasive mammary carcinomas (CMCs) resemble human breast cancer by clinics and pathology as well as behavior and prognostic indicators. We hypothesized that the current molecular classifications of human breast cancer, used for therapeutic decision, could be relevant to dogs.

methodsThree hundred and fifty female dogs with spontaneous CMC and a 2-year follow-up were retrospectively included. By immunohistochemistry, CMCs were classified according to Nielsen (Clin Cancer Res 10:5367-5374, 2004) and Blows (PlosOne doi: 10.1371/journal.pmed.1000279, 2010) into the subtypes of human breast cancer.

resultsFour immunophenotypes were defined either according to Nielsen classification (luminal A 14.3%, luminal B 9.4%, triple-negative basal-like 58.6%, and triple-negative nonbasal-like 17.7% CMCs); or to Blows classification (luminal 1-: 11.4%, luminal 1+: 12.3%, Core basal phenotype: 58.6%, and five-negative phenotype: 17.7%). No HER2-overexpressing CMC as defined by a 3 + immunohistochemical score was observed in our cohort. By univariate and multivariate analyses, both immunophenotypical classifications applied to CMCs showed strong prognostic significance: luminal A or luminal 1+ CMCs showed a significantly longer disease-free interval (HR = 0.46), Overall (HR = 0.47), and Specific Survival (HR = 0.56) compared to triple-negative carcinomas, after adjustment for stage.

conclusionsIn our cohort, triple-negative CMCs largely predominated (76%), were much more prevalent than in human beings, and showed an aggressive natural behavior after mastectomy. Dogs are thus potent valuable spontaneous models to test new therapeutic strategies for this particular subtype of breast cancer.

Indexed as

AnimalsBiomarkers, TumorDisease Models, AnimalDogsFemaleHumansImmunophenotypingMammary Neoplasms, AnimalNeoplasm InvasivenessPrognosisTriple Negative Breast NeoplasmsBiomarkers, TumorAnimal modelBreast cancerDogImmunophenotypeLuminalTriple-negative

Identifiers

PMID29063312
PMCPMC5790838
OpenAlexW2765583492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.